| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
|
Purity: ≥98%
Fosphenytoin sodium, the sodium salt form of fosphenytoin, is a prodrug of phenytoin with similar anticonvulsant properties. It is intended for parenteral administration; As a prodrug, it is hydrolyzed to the phenytoin,which is the active metabolite. Phenytoin exerts its effect most likely through an enhancement of sodium efflux from neurons in the motor cortex. This leads to a suppression of excessive neuronal firing and spread of seizure activity. Other physiologic effects from actions of phenytoin include modulation of the voltage-dependent calcium channels of neurons, inhibition of calcium flux across neuronal membranes and enhancement of sodium-potassium ATPase activity of neurons and glial cells.
| ln Vivo |
A powerful neuroprotective medication against damage brought on by ischemia is fosphenytoin. Hippocampal CA1 pyramidal neurons in rats given fosphenytoin (30 mg/kg, im) five minutes after the commencement of the ischemic episode stayed close to control levels (13.90 +/- 0.92), although there were no appreciable alterations in GFAP staining[1]. Rats given 84 mg/kg of fosphenytoin had an 83% relative bioavailability of the drug. In completely kindled female Wistar rats, fosphenytoin dose-dependently raises the focal seizure (post-discharge) threshold. Only after administering the largest dose of fosphenytoin tested (84 mg/kg) did seizure intensity and threshold duration decrease [2].
|
|---|---|
| References |
[1]. Chan SA, et al. Fosphenytoin reduces hippocampal neuronal damage in rat following transient global ischemia. Acta Neurochir (Wien). 1998;140(2):175-80.
[2]. Loscher W, et al. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin. Epilepsy Res. 1998 Mar;30(1):69-76 |
| Molecular Formula |
C16H15N2NAO6P
|
|---|---|
| Molecular Weight |
385.263635873795
|
| CAS # |
92134-98-0
|
| Related CAS # |
Fosphenytoin;93390-81-9;Fosphenytoin-d10 disodium
|
| SMILES |
C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3=CC=CC=C3.[Na+].[Na+]
|
| InChi Key |
GQPXYJNXTAFDLT-UHFFFAOYSA-L
|
| InChi Code |
InChI=1S/C16H15N2O6P.2Na/c19-14-16(12-7-3-1-4-8-12,13-9-5-2-6-10-13)17-15(20)18(14)11-24-25(21,22)23;;/h1-10H,11H2,(H,17,20)(H2,21,22,23);;/q;2*+1/p-2
|
| Chemical Name |
disodium;(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)methyl phosphate
|
| Synonyms |
Cerebyx; Pro-Epanutin; HMPDP; ACC-9653; ACC-9653; ACC9653; Fosphenytoin Sodium; Prodilantin
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~246.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (61.54 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5956 mL | 12.9782 mL | 25.9565 mL | |
| 5 mM | 0.5191 mL | 2.5956 mL | 5.1913 mL | |
| 10 mM | 0.2596 mL | 1.2978 mL | 2.5956 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA